Clinical Trial Update: Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term safety and tolerability of deutetrabenazine (TEV-50717) for Tourette syndrome in children and adolescents was terminated; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• deutetrabenazine (deutetrabenazine)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Tourette Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2021-03-23